Physician profile
Aysha Khalid
NPI 1952522732
$2,701.76
in general payments reported to CMS, 2019-2025
48 companies · $560 in 2025
The $560 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $40.84 · 2021: $86.91 · 2022: $377 · 2023: $851 · 2024: $416 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,692.55 |
| Education | $134.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $206.47 | 2019-2024 | |
| Gilead Sciences, INC. | $163.84 | 2021-2024 | Trodelvy |
| Daiichi Sankyo INC. | $162.88 | 2021-2023 | Injectafer |
| Dexcom, INC. | $160.00 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| E.R. Squibb & Sons, L.L.C. | $156.36 | 2020-2023 | Opdivo, Opdualag |
| Blueprint Medicines Corporation | $148.23 | 2023-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $137.56 | 2020-2023 | Xpovio |
| Puma Biotechnology, INC. | $133.31 | 2019-2025 | |
| Exelixis INC. | $128.47 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $126.09 | 2025 | Datroway |
| Pfizer INC. | $122.70 | 2021-2025 | |
| Mirati Therapeutics, INC. | $82.97 | 2023-2024 | Krazati |
| Abbvie INC. | $70.76 | 2023-2025 | |
| Astellas Pharma US INC | $65.35 | 2019-2025 | Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $60.34 | 2019-2024 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.91 | 2023-2025 | |
| Celgene Corporation | $48.23 | 2023-2024 | Reblozyl, Pomalyst |
| Emmaus Medical, INC. | $45.17 | 2022-2023 | Endari |
| Genzyme Corporation | $41.10 | 2020-2023 | |
| Genentech USA, INC. | $38.05 | 2023-2025 | Columvi, Lunsumio, Polivy |
| Merck Sharp & Dohme LLC | $36.44 | 2024 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Lilly USA, LLC | $29.89 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $28.42 | 2024-2025 | Orserdu |
| Emd Serono, INC. | $26.34 | 2019-2023 | Tepmetko |
| Aveo Pharmaceuticals, INC. | $26.04 | 2025 | |
| Boston Scientific Corporation | $25.46 | 2019 | |
| Apellis Pharmaceuticals, INC. | $25.32 | 2024 | Empaveli |
| Adc Therapeutics America, INC. | $21.19 | 2023 | |
| Pharmacosmos Therapeutics INC. | $20.69 | 2023 | Monoferric |
| Spectrum Pharmaceuticals INC. | $19.88 | 2023 | Rolvedon |
| Bayer Healthcare Pharmaceuticals INC. | $19.54 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.89 | 2025 | Onivyde |
| Array Biopharma INC | $18.23 | 2025 | Lorbrena, Braftovi, Mektovi |
| Deciphera Pharmaceuticals INC. | $17.50 | 2025 | Qinlock, Romvimza |
| Janssen Biotech, INC. | $17.34 | 2024 | Darzalex, Tecvayli, Talvey |
| Geron Corporation | $17.06 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $16.80 | 2023 | Ultomiris |
| Jazz Pharmaceuticals INC. | $16.66 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.56 | 2023 | Pyrukynd |
| Sumitomo Pharma America, INC. | $16.12 | 2023 | Orgovyx |
| Incyte Corporation | $15.34 | 2023 | Jakafi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2019 | |
| Sobi, INC | $14.24 | 2024 | |
| Seagen INC. | $13.68 | 2019 | |
| Beigene USA, INC. | $13.56 | 2024 | Brukinsa |
| Lexicon Pharmaceuticals, INC. | $13.40 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aysha Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.